MX2016013434A - Inhibidores potentes y selectivos del virus de la hepatitis c. - Google Patents

Inhibidores potentes y selectivos del virus de la hepatitis c.

Info

Publication number
MX2016013434A
MX2016013434A MX2016013434A MX2016013434A MX2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A
Authority
MX
Mexico
Prior art keywords
virus
hepatitis
potent
selective inhibitors
compounds
Prior art date
Application number
MX2016013434A
Other languages
English (en)
Inventor
Junxing Shi
Steven J Coats
Richard Anthony Whitaker
Raymond F Schinazi
Amblard Franck
Rosario Mcbrayer Tamara
Zhang Hongwang
Zhou Longhu
Original Assignee
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma Inc filed Critical Cocrystal Pharma Inc
Publication of MX2016013434A publication Critical patent/MX2016013434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos, composiciones y métodos para tratar o prevenir la infección por el virus de la hepatitis C (HCV) en sujetos humanos u otros huéspedes animales. Los compuestos son también sales profármacos farmacéuticamente aceptables y otros derivados de los mismos como composiciones farmacéuticas y métodos para el tratamiento o la prevención de la infección por el HCV.
MX2016013434A 2014-04-15 2015-04-15 Inhibidores potentes y selectivos del virus de la hepatitis c. MX2016013434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980016P 2014-04-15 2014-04-15
PCT/US2015/025903 WO2015160907A2 (en) 2014-04-15 2015-04-15 Potent and selective inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
MX2016013434A true MX2016013434A (es) 2017-03-03

Family

ID=54324704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013434A MX2016013434A (es) 2014-04-15 2015-04-15 Inhibidores potentes y selectivos del virus de la hepatitis c.

Country Status (14)

Country Link
US (1) US9926295B2 (es)
EP (1) EP3131892A4 (es)
JP (1) JP2017513852A (es)
KR (1) KR20170002407A (es)
CN (1) CN106661004A (es)
AU (1) AU2015247706A1 (es)
BR (1) BR112016023833A2 (es)
CA (1) CA2945514A1 (es)
IL (1) IL248318A0 (es)
MX (1) MX2016013434A (es)
PH (1) PH12016502039A1 (es)
RU (1) RU2016144076A (es)
SG (1) SG11201608587QA (es)
WO (1) WO2015160907A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
EP3021845A1 (en) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2019265740A1 (en) * 2018-05-09 2020-10-29 Cocrystal Pharma, Inc. Combination therapy for treatment of HCV
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2242752T3 (da) * 2008-02-13 2012-11-19 Bristol Myers Squibb Co Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer
CN102395590A (zh) * 2009-02-06 2012-03-28 Rfs制药公司 用于治疗癌症和病毒感染的嘌呤核苷单磷酸酯前药
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2809261A1 (en) * 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
CN103328466B (zh) * 2010-11-01 2016-08-03 Rfs制药公司 Hcv ns3蛋白酶抑制剂

Also Published As

Publication number Publication date
BR112016023833A2 (pt) 2017-10-10
EP3131892A4 (en) 2017-09-20
SG11201608587QA (en) 2016-11-29
PH12016502039A1 (en) 2017-01-09
RU2016144076A (ru) 2018-05-16
WO2015160907A3 (en) 2016-12-01
JP2017513852A (ja) 2017-06-01
KR20170002407A (ko) 2017-01-06
US20170029407A1 (en) 2017-02-02
IL248318A0 (en) 2016-11-30
AU2015247706A1 (en) 2016-10-27
WO2015160907A2 (en) 2015-10-22
US9926295B2 (en) 2018-03-27
EP3131892A2 (en) 2017-02-22
CA2945514A1 (en) 2015-10-22
CN106661004A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2012027712A3 (en) Potent and selective inhibitors of hepatitis c virus
PH12016501750A1 (en) Human plasma kallikrein inhibitors
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
PH12016502039A1 (en) Potent and selective inhibitors of hepatitis c virus
NZ733174A (en) Quinazoline derivatives used to treat hiv
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
NZ703064A (en) Inhibitors of hepatitis c virus
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
PH12017501272A1 (en) Indole derivatives as dengue viral replication inhibitors
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2019004029A (es) Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors